Diarrhoea-associated haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infections in New Zealand children: Clinical features and short-term complications from a 23-year cohort study.
haemolytic uraemic syndrome
nephrology/renal
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
26
12
2022
received:
25
10
2022
accepted:
08
01
2023
medline:
30
3
2023
pubmed:
20
1
2023
entrez:
19
1
2023
Statut:
ppublish
Résumé
Diarrhoea-associated haemolytic uraemic syndrome (D+HUS) is an important cause of acute kidney injury (AKI) in young children and it is most commonly associated with Shiga toxin-producing Escherichia coli (STEC). Gastrointestinal infections caused by STEC have been increasing in New Zealand over the past two decades, but little is known regarding the acute and short-term outcomes of New Zealand children who develop D+HUS. To describe the clinical characteristics, complications and short-term outcomes of New Zealand children with D+HUS identified between 1 January 1998 and 31 December 2020. The New Zealand Paediatric Surveillance Unit sends out a monthly survey to all practising paediatricians regarding conditions under active surveillance. Paediatricians caring for a child aged 0-15 years of age with D+HUS over the prior month were requested to report their patient. Reporting clinicians were then contacted by the principal investigator and sent a questionnaire requesting patient clinical and laboratory information. Two hundred and twenty-six children had D+HUS; median age 2.8 years (interquartile range 1.7-4.9). Acute dialysis was required in 128/226 (56.2%) of children for a median of 9 days (range 1-38). Children with shorter diarrhoeal prodrome, higher neutrophil count and haemoglobin had a longer duration of dialysis. Seizures occurred in 31/226 (13.7%) and were not associated with a greater HUS severity score. Acute mortality was 1.3%, all resulting from thrombotic microangiopathic cerebral injury. D+HUS is a major cause of AKI in previously healthy young children. Earlier recognition of STEC infections in young children may reduce the need for dialysis and other extra-renal complications. The New Zealand incidence of acute dialysis, other major complications and mortality are consistent with other reported studies.
Sections du résumé
BACKGROUND
Diarrhoea-associated haemolytic uraemic syndrome (D+HUS) is an important cause of acute kidney injury (AKI) in young children and it is most commonly associated with Shiga toxin-producing Escherichia coli (STEC). Gastrointestinal infections caused by STEC have been increasing in New Zealand over the past two decades, but little is known regarding the acute and short-term outcomes of New Zealand children who develop D+HUS.
AIM
To describe the clinical characteristics, complications and short-term outcomes of New Zealand children with D+HUS identified between 1 January 1998 and 31 December 2020.
METHODS
The New Zealand Paediatric Surveillance Unit sends out a monthly survey to all practising paediatricians regarding conditions under active surveillance. Paediatricians caring for a child aged 0-15 years of age with D+HUS over the prior month were requested to report their patient. Reporting clinicians were then contacted by the principal investigator and sent a questionnaire requesting patient clinical and laboratory information.
RESULTS
Two hundred and twenty-six children had D+HUS; median age 2.8 years (interquartile range 1.7-4.9). Acute dialysis was required in 128/226 (56.2%) of children for a median of 9 days (range 1-38). Children with shorter diarrhoeal prodrome, higher neutrophil count and haemoglobin had a longer duration of dialysis. Seizures occurred in 31/226 (13.7%) and were not associated with a greater HUS severity score. Acute mortality was 1.3%, all resulting from thrombotic microangiopathic cerebral injury.
CONCLUSION
D+HUS is a major cause of AKI in previously healthy young children. Earlier recognition of STEC infections in young children may reduce the need for dialysis and other extra-renal complications. The New Zealand incidence of acute dialysis, other major complications and mortality are consistent with other reported studies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-498Informations de copyright
© 2023 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Besser RE, Griffin PM, Slutsker L. Escherichia coli O157:H7 gastroenteritis and the hemolytic uremic syndrome: An emerging infectious disease. Annu. Rev. Med. 1999; 50: 355-67.
Johnson S, Taylor CM. What's new in haemolytic uraemic syndrome? Eur. J. Pediatr. 2008; 167: 965-71.
Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur. J. Pediatr. 2010; 169: 7-13.
Ball EF, Kara T. Epidemiology and outcome of acute kidney injury in New Zealand children. J. Paediatr. Child Health 2008; 44: 642-6.
Khalid M, Andreoli S. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr. Nephrol. 2019; 34: 2495-507.
Gallo EG, Gianantonio CA. Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr. Nephrol. 1995; 9: 117-9.
Wong W. Shiga toxin producing Escherichia coli infections and associated haemolytic uraemic syndrome in New Zealand children: Twenty three years of epidemiology and clinical observations. Int. J. Pediatr. Res. 2021; 8: 085.
Ardissino G, Tel F, Testa S et al. A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: Data from the ItalKid-HUS network. Eur. J. Pediatr. 2018; 177: 1667-74.
Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat. Rev. Nephrol. 2012; 8: 658-69.
Hickey CA, Beattie TJ, Cowieson J et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch. Pediatr. Adolesc. Med. 2011; 165: 884-9.
Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr. Nephrol. 2012; 27: 1407-10.
Ardissino G, Tel F, Possenti I et al. Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics 2016; 137: e20152153. https://doi.org/10.1542/peds.2015-2153
Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygård K, Bjerre A. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: A nationwide retrospective study from 1999-2008. BMC Infect. Dis. 2016; 13: 285.
Jacquinet S, De Rauw K, Pierard D et al. Haemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015. Arch. Public Health 2018; 76: 41.
Loos S, Ahlenstiel T, Kranz B et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: Presentation and short-term outcome in children. Clin. Infect. Dis. 2012; 55: 753-9.
Hahn JS, Havens PL, Higgins JJ, O'Rourke PP, Estroff JA, Strand R. Neurological complications of hemolytic-uremic syndrome. J. Child Neurol. 1989; 4: 108-13.
Nathanson S, Kwon T, Elmaleh M et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2010; 5: 1218-28.
Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr. Nephrol. 2019; 34: 1485-92.
Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T. Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine 2015; 94: e1000.
Rahman RC, Cobeñas CJ, Drut R et al. Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: Retrospective analysis of 54 children. Pediatr. Nephrol. 2012; 27: 229-33.
Ardissino G, Daccò V, Testa S et al. Hemoconcentration: A major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr. Nephrol. 2015; 30: 345-52.
Ninchoji T, Nozu K, Nakanishi K et al. Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: A single center experience. Clin. Exp. Nephrol. 2017; 21: 889-94.